Identifying Risk Factors for Gram-negative Resistance for HAP/VAP in the Intensive Care Unit

Methodist Health System

Status: Completed

Conditions: Ventilator-associated Pneumonia; Hospital-acquired Pneumonia

Treatments: Other: Observational

Study type: Observational

Funder types: Other

Identifiers

NCT04700202

046.PHA.2020.D

Details and patient eligibility

About

Single center, retrospective chart review. Patients admitted to MDMC ICU from 4/1/2017 to 6/30/2020 will be identified through the electronic medical record utilizing ICD codes for HAP and VAP.

Full description

Single center, retrospective chart review. Patients admitted to MDMC ICU from 4/1/2017 to 6/30/2020 will be identified through the electronic medical record utilizing ICD codes for HAP and VAP. Patients with respiratory culture data signifying a Gram-negative organism as the cause of HAP/VAP will be analyzed as described below if study inclusion criteria is met. Minimum inhibitory concentration (MIC) data will interpreted per Clinical & Laboratory Standards Institute (CLSI) standards to determine local patterns of resistance. Multivariable logistic regression will be performed to determine risk factors for piperacillin-tazobactam, cefepime or meropenem resistant Gram-negative isolates. Project target date of completion and close-out is May 2021.

Enrollment: 132 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• ICU, Neuro critical care unit admission
• Diagnosis of HAP or VAP
• Respiratory culture positive for Gram-negative organism

Exclusion criteria

• ICU length of stay <48 hours prior to HAP/VAP
• Culture or MIC data unavailable
• Pregnant

Trial design

132 participants in 1 patient group

Retrospective Cohort

Description:

Patients admitted to MDMC ICU from 4/1/2017 to 6/30/2020 will be identified through the electronic medical record utilizing ICD codes for HAP and VAP.

Treatment:

Other: Observational